Among cancer survivors, the incidence of therapy-related myeloid neoplasms (t-MN) definitely called for urgent action. Although it is rare in the general population, one of 200 breast cancer patients, one of 10 patients treated for non-Hodgkin lymphoma and up to 1.0% of children treated for hematological, solid and central nervous system cancers develope t-MN.

Prompted by a story of positive interaction between NAnA an energetic small Patient Advocacy Organization (PAO) and the European research group led by Prof. MT Voso at University of Tor Vergata (Rome), the workshop focused on t-MN scientific knowledge and tools for the recognition and clinical management of t-MN, with the aim of creating a constructive debate for innovative point-of-views and essential advancements in the field.

Skilled European researchers gathered in Rome to discuss prevention and cure t-MN development, investigating the type and dosage of cancer therapy, aging process, inherited and environmental risk factors and genetic abnormalities in haematopoietic stem cells. Discussions converged on a Research and Innovation Agenda regarding t-MN, with a dual focus on translation from research to the bed side and industry as well as on health-related quality of life (HRQOL) for cancer survivors. Representatives of European Patient Advocacy Organizations and industry were invited at the Round table “The patient social point of view”.

4 abstracts by early career scientists (below the age of 40) were selected for oral presentation at the workshop. A few travel and lodging grants were available.

This workshop was funded by the European Joint Programme on Rare Diseases. Registration was required. The Abstract book was made available online to all registered participants.